|
Orthologous residues
|
|
AP2M1 (human): T156‑p, AP2M1 iso2 (human): T154‑p, AP2M1 (mouse): T156‑p, AP2M1 (rat): T156‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site
|
|
Relevant cell lines - cell types - tissues:
A549 (pulmonary), OK (renal)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
opossum
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
dopamine
|
|
|
|
increase
|
|
|
bisindolylmaleimide
|
dopamine
|
|
|
inhibit treatment-induced increase
|
|
|
staurosporine
|
dopamine
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
ATP1A1 (human)
|
|
Not reported
|
intracellular localization
|
|
co-immunoprecipitation
|
|
|
Comments:
important for endocytosis
|
